|
|
|
|
|
| Matos,D.M.; Rizzatti,E.G.; Garcia,A.B.; Gallo,D.A.P.; Falcão,R.P.. |
| We evaluated the expression of 10 adhesion molecules on peripheral blood tumor cells of 17 patients with chronic lymphocytic leukemia, 17 with mantle-cell lymphoma, and 13 with nodal or splenic marginal B-cell lymphoma, all in the leukemic phase and before the beginning of any therapy. The diagnosis of B-cell non-Hodgkin's lymphomas was based on cytological, histological, immunophenotypic, and molecular biology methods. The mean fluorescence intensity of the adhesion molecules in tumor cells was measured by flow cytometry of CD19-positive cells and differed amongst the types of lymphomas. Comparison of chronic lymphocytic leukemia and mantle-cell lymphoma showed that the former presented a higher expression of CD11c and CD49c, and a lower expression of... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Non-Hodgkin's lymphoma; Adhesion molecules; Flow cytometry; CD49c/CD49d. |
| Ano: 2006 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006001000011 |
| |
|
|
| De Souza,C.A.; Santini,G.; Marino,G.; Nati,S.; Congiu,A.M.; Vigorito,A.C.; Damasio,E.. |
| Clinical trials indicate that amifostine may confer protection on various normal tissues without attenuating anti-tumor response. When administered prior to chemotherapy or radiotherapy, it may provide a broad spectrum of cytoprotection including against alkylating drugs. The mechanism of protection resides in the metabolism at normal tissue site by membrane-bound alkaline phosphatase. Toxicity of this drug is moderate with hypotension, nausea and vomiting, and hypocalcemia being observed. We report a phase II study using amifostine as a protective drug against high-dose cyclophosphamide (HDCY) (7 g/m2), used to mobilize peripheral blood progenitor cells (PBPC) and to reduce tumor burden. We enrolled 29 patients, 22 (75.9%) affected by aggressive and 7... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Amifostine; Cytoprotection; Non-Hodgkin's lymphoma; High-dose cyclophosphamide; Peripheral blood progenitor cell mobilization. |
| Ano: 2000 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2000000700009 |
| |
|
|
| Figueirêdo,Camila Bezerra Melo; Souza,Joelma Rodrigues de; Soares,Daniel Handerson Galindo; Silva,Caio Cesar de Andrade Rodrigues; Lorena,Virginia Maria Barros de. |
| Non-Hodgkin's lymphoma (NHL) consists of a group of neoplasias involving mainly B cells and represents 90% of all lymphomas. The current available therapy is based on chemotherapy associated with the monoclonal antibody rituximab (Mab Thera(r)), which targets the CD20 protein, present in over 80% of NHL mature B cells. Recent clinical reports show a preference for combining the benefits of immunotherapy and adjuvant chemotherapy, thus generating safe and effective alternative treatments. The current review aimed at evaluating various aspects related to the use of rituximab for NHL, highlighting the possible inhibitory mechanisms of cell proliferation, the achieved clinical results, and the expected clinical and economic outcomes of treatments. The results... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Non-Hodgkin's lymphoma; Antineoplastic combined chemotherapy/protocols; Adjuvant chemotherapy; Rituximab/application/Non-Hodgkin's lymphoma. |
| Ano: 2014 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502014000300445 |
| |
|
|
|
